TY - JOUR
T1 - Can we incorporate MRD assessment into clinical practice in AML?
AU - Ossenkoppele, Gert
AU - Schuurhuis, Gerrit Jan
AU - van de Loosdrecht, Arjan
AU - Cloos, Jacqueline
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Measurable residual disease (MRD) can be assessed either by flow cytometry or molecular techniques. It has been proven to be highly prognostic in quite a number of prospective clinical studies. The recently published ELN MRD recommendations aim harmonize the approaches to MRD assessment in order to improve its overall quality. The predictive value leading to the usage as a surrogate endpoint for survival which would be instrumental for faster drug approvals has still to be proven. Nevertheless, many AML centers use MRD status to inform treatment.
AB - Measurable residual disease (MRD) can be assessed either by flow cytometry or molecular techniques. It has been proven to be highly prognostic in quite a number of prospective clinical studies. The recently published ELN MRD recommendations aim harmonize the approaches to MRD assessment in order to improve its overall quality. The predictive value leading to the usage as a surrogate endpoint for survival which would be instrumental for faster drug approvals has still to be proven. Nevertheless, many AML centers use MRD status to inform treatment.
KW - AML
KW - Allogeneic stem cell transplantation
KW - Leukemic stem cells
KW - Measurable residual disease (MRD)
KW - Multicolor flowcytometry
KW - qPCR
UR - http://www.scopus.com/inward/record.url?scp=85065626340&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.beha.2019.05.003
DO - https://doi.org/10.1016/j.beha.2019.05.003
M3 - Review article
C2 - 31204000
SN - 1521-6926
VL - 32
SP - 186
EP - 191
JO - Best Practice and Research: Clinical Haematology
JF - Best Practice and Research: Clinical Haematology
IS - 2
ER -